Xiaoshi Zhang

1.3k total citations
34 papers, 428 citations indexed

About

Xiaoshi Zhang is a scholar working on Molecular Biology, Oncology and Radiation. According to data from OpenAlex, Xiaoshi Zhang has authored 34 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Radiation. Recurrent topics in Xiaoshi Zhang's work include Melanoma and MAPK Pathways (9 papers), Advanced X-ray Imaging Techniques (7 papers) and Laser-Plasma Interactions and Diagnostics (4 papers). Xiaoshi Zhang is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), Advanced X-ray Imaging Techniques (7 papers) and Laser-Plasma Interactions and Diagnostics (4 papers). Xiaoshi Zhang collaborates with scholars based in China, United States and Taiwan. Xiaoshi Zhang's co-authors include Charles S. Bevis, Elisabeth R. Shanblatt, Christina L. Porter, Henry C. Kapteyn, Michael Tanksalvala, Robert Karl, Margaret M. Murnane, Daniel E. Adams, Benjamin Galloway and Dennis F. Gardner and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Xiaoshi Zhang

29 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoshi Zhang China 12 186 121 94 91 63 34 428
Konstanze von König Germany 5 139 0.7× 129 1.1× 34 0.4× 26 0.3× 54 0.9× 6 397
Hisako Nakano Japan 11 326 1.8× 84 0.7× 67 0.7× 20 0.2× 21 0.3× 31 533
A. Franchi Italy 16 341 1.8× 25 0.2× 49 0.5× 48 0.5× 7 0.1× 50 836
Christian Siebenwirth Germany 14 231 1.2× 301 2.5× 32 0.3× 9 0.1× 20 0.3× 25 668
V. Hable Germany 20 362 1.9× 386 3.2× 84 0.9× 12 0.1× 11 0.2× 26 931
José M. Martín-García United States 13 354 1.9× 32 0.3× 9 0.1× 16 0.2× 26 0.4× 40 578
N. F. Metting United States 15 158 0.8× 152 1.3× 119 1.3× 29 0.3× 3 0.0× 24 667
J. Szabó Hungary 15 398 2.1× 130 1.1× 49 0.5× 14 0.2× 2 0.0× 53 694
Andrey S. Sokolov Russia 13 186 1.0× 56 0.5× 22 0.2× 5 0.1× 7 0.1× 34 323
K. Wang China 11 104 0.6× 43 0.4× 52 0.6× 177 1.9× 51 562

Countries citing papers authored by Xiaoshi Zhang

Since Specialization
Citations

This map shows the geographic impact of Xiaoshi Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoshi Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoshi Zhang more than expected).

Fields of papers citing papers by Xiaoshi Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoshi Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoshi Zhang. The network helps show where Xiaoshi Zhang may publish in the future.

Co-authorship network of co-authors of Xiaoshi Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoshi Zhang. A scholar is included among the top collaborators of Xiaoshi Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoshi Zhang. Xiaoshi Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Jinlong, Dongmei Yan, Xiaorui Liu, & Xiaoshi Zhang. (2025). High-frequency KRAS mutations in pancreatic adenocarcinoma: prognostic significance and potential co-targeting therapies. Translational Cancer Research. 14(4). 2331–2342.
2.
Gu, Junjie, Jun Guo, Yu Jiang, et al.. (2024). FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: A phase 1B dose-expansion study.. Journal of Clinical Oncology. 42(16_suppl). 3095–3095. 1 indexed citations
3.
Wei, Xiaoting, Zhengyun Zou, Weizhen Zhang, et al.. (2024). Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 9545–9545. 3 indexed citations
4.
Li, Dandan, et al.. (2024). Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence. Journal of Neuro-Oncology. 170(3). 665–673. 2 indexed citations
5.
Qu, Ailin, Qian Wang, Qing Chang, et al.. (2023). Prognostic and predictive value of a lncRNA signature in patients with stage II colon cancer. Scientific Reports. 13(1). 1350–1350. 4 indexed citations
6.
Si, Lu, Zhengyun Zou, Weizhen Zhang, et al.. (2023). Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9510–9510. 5 indexed citations
7.
Wen, Xizhi, Leyi Yao, Zhenlong Shao, et al.. (2021). Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling. Frontiers in Oncology. 11. 698888–698888. 3 indexed citations
8.
Ge, Wenjie, Yu Wang, Shanliang Zheng, et al.. (2021). Nuclear iASPP determines cell fate by selectively inhibiting either p53 or NF-κB. Cell Death Discovery. 7(1). 195–195. 5 indexed citations
9.
Zhang, Xiaoshi, Lutao Du, Jingyi Han, et al.. (2020). Novel long non‐coding RNA LINC02323 promotes epithelial‐mesenchymal transition and metastasis via sponging miR‐1343‐3p in lung adenocarcinoma. Thoracic Cancer. 11(9). 2506–2516. 20 indexed citations
10.
Si, Lu, Xiaoshi Zhang, Sang Joon Shin, et al.. (2020). Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. European Journal of Cancer. 135. 31–38. 12 indexed citations
11.
Li, Yan, Shuhai Lin, Lei Li, et al.. (2018). PDSS2 Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose Metabolism. Cancer Research. 78(16). 4471–4481. 34 indexed citations
12.
Zhang, Xiaoshi, et al.. (2018). A tabletop coherent EUV source for commercial EUVL metrology and imaging applications. 72–72. 1 indexed citations
13.
Si, Lu, Xiaoshi Zhang, Zhen Xu, et al.. (2018). Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer. 18(1). 520–520. 9 indexed citations
14.
Wei, Weiyuan, Lei Li, Xiaotong Wang, et al.. (2015). Overexpression of caudal type homeobox transcription factor 2 inhibits the growth of the MGC-803 human gastric cancer cell line in vivo. Molecular Medicine Reports. 12(1). 905–912. 1 indexed citations
15.
Cao, Xiaofei, et al.. (2014). HoxA10 Induces Proliferation in Human Prostate Carcinoma PC-3 Cell Line. Cell Biochemistry and Biophysics. 70(2). 1363–1368. 14 indexed citations
16.
Wen, Meiling, et al.. (2014). Clinical significance of aberrant mammalian target of rapamycin expression in stage IIIB colon cancer. Oncology Letters. 8(3). 1080–1086. 4 indexed citations
17.
Zhang, Jian, Yi Zhang, Xiaoshi Zhang, et al.. (2014). A Functional TNFAIP2 3'-UTR rs8126 Genetic Polymorphism Contributes to Risk of Esophageal Squamous Cell Carcinoma. PLoS ONE. 9(11). e109318–e109318. 18 indexed citations
18.
Yu, Jinlong, et al.. (2014). Patchouli alcohol protects against lipopolysaccharide-induced acute lung injury in mice. Journal of Surgical Research. 194(2). 537–543. 31 indexed citations
19.
Zhang, Xiaoshi, et al.. (2001). Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.. PubMed. 22(8). 731–5. 12 indexed citations
20.
Colby, Howard D., et al.. (2001). Bufuralol Metabolism by Guinea Pig Adrenal and Hepatic Microsomes. Pharmacology. 62(4). 229–233. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Konstanze von König Breakdown of academic impact, for papers by Hisako Nakano Breakdown of academic impact, for papers by A. Franchi Breakdown of academic impact, for papers by Christian Siebenwirth Breakdown of academic impact, for papers by V. Hable Breakdown of academic impact, for papers by José M. Martín-García Breakdown of academic impact, for papers by N. F. Metting Breakdown of academic impact, for papers by J. Szabó Breakdown of academic impact, for papers by Andrey S. Sokolov Breakdown of academic impact, for papers by K. Wang
Rankless by CCL
2026